JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traynor, J. R.
Right arrow Articles by Remmers, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traynor, J. R.
Right arrow Articles by Remmers, A. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 300, Issue 1, 157-161, January 2002

Relationship between Rate and Extent of G Protein Activation: Comparison between Full and Partial Opioid Agonists

John R. Traynor, Mary J. Clark and Ann E. Remmers

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan

Opioid agonists acting at their receptors alter intracellular events by initiating activation of various types of Gi/Go proteins. This can be measured by the binding of the stable GTP analog [35S]guanosine-5'-O-(3-thio)triphosphate ([35S]GTPgamma S). In this study agonist efficacy is defined by the degree to which an opioid stimulates the binding of [35S]GTPgamma S. This allows for a definition of full and partial agonists; a full agonist causing a greater stimulation of [35S]GTPgamma S binding than a partial agonist. The hypothesis that the rate of agonist-stimulated [35S]GTPgamma S binding is dependent upon agonist efficacy was tested using membranes from C6 glioma cells expressing µ- or delta -opioid receptors. At maximal concentrations the rate of agonist-stimulated [35S]GTPgamma S binding followed the efficacy of µ-agonists in stimulating [35S]GTPgamma S binding, i.e., [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin > morphine > meperidine > butorphanol > nalbuphine. At submaximal concentrations of µ- or delta -full agonists the [35S]GTPgamma S association rate was also reduced, such that the rate of [35S]GTPgamma S binding correlated with the extent of [35S]GTPgamma S bound, whether this binding was stimulated by a full agonist or a partial agonist. Agonists also stimulated [35S]GTPgamma S dissociation, showing that binding of this stable nucleotide was reversible. Comparison of the delta -agonists [D-Ser2,Leu5]-enkephalin-Thr and (±)-4-((alpha -R*)-alpha -((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxylbenzyl)-N,N-diethylbenzamide, a compound with slow dissociation kinetics, showed the measured rate of G protein activation was not influenced by the agonist switching between receptors. The results are consistent with the idea that the active state(s) of the receptor induced by full or partial agonists is the same, but the number of activated receptors determines the rate of G protein activation.


0022-3565/02/3001-0157$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. J. Clark, J. J. Linderman, and J. R. Traynor
Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial {micro}-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model
Mol. Pharmacol., May 1, 2008; 73(5): 1538 - 1548.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J.-X. Li, G. L. Becker, J. R. Traynor, Z.-H. Gong, and C. P. France
Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 227 - 236.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. M. Raehal, J. J. Lowery, C. M. Bhamidipati, R. M. Paolino, J. R. Blair, D. Wang, W. Sadee, and E. J. Bilsky
In Vivo Characterization of 6{beta}-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1150 - 1162.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Zollner, M. A. Shaqura, C. P. Bopaiah, S. Mousa, C. Stein, and M. Schafer
Painful Inflammation-Induced Increase in {micro}-Opioid Receptor Binding and G-Protein Coupling in Primary Afferent Neurons
Mol. Pharmacol., August 1, 2003; 64(2): 202 - 210.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.